Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0142-0000-0002
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
NNC0142-0000-0002 (also known as JNJ-64304500) is an investigational human immunoglobulin G4 (IgG4) monoclonal antibody that targets the natural killer group 2 member D (NKG2D) receptor. Developed by Novo Nordisk and later evaluated in collaboration with Janssen (Johnson & Johnson), the drug is designed to block the interaction between NKG2D and its ligands, which are overexpressed in inflamed tissues. By suppressing the activity of NKG2D-expressing cells, such as T cells and natural killer (NK) cells, the antibody aims to reduce mucosal damage and inflammation in conditions like Crohn's disease and rheumatoid arthritis. Clinical trials have explored its efficacy as a subcutaneous injection, though primary endpoints in some Phase 2 trials for Crohn's disease were not met.
- Other names
- anti-NKG2Danti-NKG-2Danti-NKG 2D
02
Targets
NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on NNC0142-0000-0002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0142-0000-0002.